Wemade Heralds Special MIR4 Global New Year’s Event
14.12.2021 08:28:00 EET | Business Wire | Press release
In exciting news for MMORPG ‘MIR4’ fans, Wemade is celebrating the New Year with a special event, beginning December 14th and continuing into 2022. The opening of a new region, Phantasia, and new content updates for Boss Raid and character NFT releases will follow on December 21st.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211212005117/en/
Wemade celebrates the New Year with a special event, beginning December 14th and continuing into 2022 for MIR4 fans. The opening of a new region, Phantasia, and new content updates for Boss Raid and character NFT releases will follow on December 21st. Throughout the four-week-long event, players can receive an abundance of special rewards, including Epic Challenge Incense Burner Box, Socks of Wishes, and Cordials that can be consumed to support the growth of a character. (Graphic: Business Wire)
Throughout the four-week-long event, players can receive an abundance of special rewards, including: Epic Challenge Incense Burner Box, Socks of Wishes (containing Magic Square tickets, Secret Peak tickets), and Cordials that can be consumed to support the growth of a character. There will also be a hunting event for two weeks from December 28th. Players can obtain Wish Letters by hunting monsters in the MIR continent and exchange these from NPCs in town to get various Enhancement Stones and Blue Dragon Statues.
The release of Phantasia will reveal a completely new area of the MIR continent. This new expansion will unveil fields such as: the Phantasia Desert, Ant Hole, Sabuk Province, and Sabuk Castle Underground Jail. Players will be able to enjoy a vast amount of newly added quests, missions, and requests. ‘MIR4’ will also increase the maximum level limit to 130 as part of this update. Conquest structures’ maximum stage levels will also be increased to stage 17 – when the Tower of Conquest reaches stage 17, players will be eligible to reach the maximum level 130 for their characters.
Other new content will be updated to enable further character growth:
- The maximum constitution tier will increase to Tier 13
- Three Inner Forces will be unlocked (Violet Mist Art, Northern Profound Art, and Toad Stance)
- A new mystery, Bok Yangjeo, will be added
Additional content updates for high-level players will include:
- Boss Raid ‘Forsaken King’
- Boss Raid ‘Crimson Dragon Nest’
- Clan Expedition ‘Blue Thunder Dragon’
December 21st will set the launch of a new NFT exchange where characters can be traded. Players will be able to seal characters that are above level 60 and have a Power Score of 100,000 or more, and exchange with other players as NFTs. Players will gain recognition for ownership of their characters they have worked so hard to raise and will be able to conduct player-to-player trades using a safe and secure transaction system in the NFT exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211212005117/en/
Contact information
Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee, PR Manager
yeonghyun@wemade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom